Tech Digest

DARPA, Hurricanes, and the Zika Virus

Stay Up to Date!

Simply enter your email below and click SIGN UP!

From Bioscience Expert Patrick Cox - The Most Life-Changing Book You'll Read This Year - Click Here

September 25, 2017

Dear Reader,

Zika eradication programs seemed to be working. That was before Hurricanes Harvey, Irma, and Maria wrecked infrastructures in Florida, Texas, and Puerto Rico. Now, all three regions are water-logged mosquito nurseries, and Puerto Rico may not have basic services for months. That means that mosquito control efforts will suffer.

In fact, many mosquitoes that spread the Zika virus have meteorologically relocated. So we can expect outbreaks in new locales.

The Rise of Treatment Resistant Superbugs

A new CDC report confirmed that Aedes aegypti and Aedes albopictus mosquitoes can thrive in most of the US. These are the types that carry dangerous viruses including Zika, yellow fever, dengue, and chikungunya.  

We already knew this, though. These mosquitoes and the diseases they carried, including malaria, were once endemic in the US. DDT changed that, but then it was banned. Despite the return of limited DDT usage, disease-carrying mosquitoes continue to spread into welcoming habitats.

The diseases carried by mosquitoes keep evolving. Many have developed resistances to once effective medications. This includes a new super-malaria, spreading rapidly in Southeast Asia. Researchers warn that international travel and wind-blown mosquitoes could make this a global problem. 

2017 marks the end of a record 12-year break during which no Category 3–5 hurricanes hit the US mainland. The longest previous record was an 8-year period between 1860 and 1869.

I think it’s unlikely that 2017 will be an anomaly. Hurricanes have historically come in cycles. Ten Category 4 or 5 storms made landfall on the US in the 50 years between 1920–1969. Only three have come onshore in the 46-year period since then. Clearly, we’re overdue for more.

I don’t know if it’s possible for humans to affect climate, but I’m 100% certain that nothing can be done that would have any real impact on weather for decades. As a result, there will be ample opportunities for virus-carrying mosquitos to extend their reach.

So we had better be prepared.

New Approaches to Infectious Disease

There is excellent progress being made in the fight against mosquito-borne pathogens. That progress comes out of entirely new approaches to infectious diseases and has the potential to end most contagious diseases.

The most obvious field of research is vaccines, but that will never be enough. We know that some of the population is vaccinophobic. Also, vaccines usually require several weeks to trigger an immune response. Giving someone a flu vaccine after they’ve contracted the influenza virus is useless.

More conventionally, monoclonal antibodies (mABs) skip the process of developing immunities. These drugs are antibodies produced by cloned cells that have already developed immunities to a disease.

Other drugs take this approach even farther. They use engineered genes that express disease-fighting antibodies.

Another solution comes from the field of nanobiotechnology. These engineered molecules act like microscopic Venus flytraps. They trap viruses in polymer nanovesicles that pass harmlessly from the body.

There is no doubt that science can solve the problem of infectious diseases. In fact, solutions already exist. Many of these technologies face a long, costly regulatory approval process, but they’re on their way. Ironically, most have received assistance from the Defense Advanced Research Projects Agency (DARPA).

This probably shouldn’t surprise you. American soldiers are often called to work in parts of the world with severe disease problems. They also face the threat of bioweapons (pathogens) deployed for military or terrorist reasons.

It may be a sign of the times that many scientists working in infectious disease are critical of the FDA but supportive of DARPA. I’ve heard from more than one scientist that the Defense Department’s new technology division is the most important force for progress against infectious diseases today.

DARPA’s main function is only to identify and nurture scientific breakthroughs that offer solutions to natural and manmade threats. So it can fund early research and trials, but it can’t take a drug all the way through the costly clinical trial process.

For those interested in seeing cures for the big killers, DARPA is an important resource. If you’d like to follow some the agency’s work in biotech and other fields, much of DARPA’s research is online here.

Patrick Cox
Patrick Cox
Editor, Transformational Technology Alert

Mauldin Economics


Stay in the Loop on Life-Extending Research
with Patrick Cox's Tech Digest

Tech Digest

Your privacy is very important to us. Please review our Privacy Policy.


« Back to Articles

From Bioscience Expert Patrick Cox - The Most Life-Changing Book You'll Read This Year - Click Here

Discuss This


We welcome your comments. Please comply with our Community Rules.


Sep. 25, 2017, 11:27 a.m.

You said: “I don’t know if it’s possible for humans to affect climate”. Seriously?

You just lost all credibility as a science writer. You choose to believe alternate facts, and that is unforgivable.

Use of this content, the Mauldin Economics website, and related sites and applications is provided under the Mauldin Economics Terms & Conditions of Use.

Unauthorized Disclosure Prohibited

The information provided in this publication is private, privileged, and confidential information, licensed for your sole individual use as a subscriber. Mauldin Economics reserves all rights to the content of this publication and related materials. Forwarding, copying, disseminating, or distributing this report in whole or in part, including substantial quotation of any portion the publication or any release of specific investment recommendations, is strictly prohibited.
Participation in such activity is grounds for immediate termination of all subscriptions of registered subscribers deemed to be involved at Mauldin Economics’ sole discretion, may violate the copyright laws of the United States, and may subject the violator to legal prosecution. Mauldin Economics reserves the right to monitor the use of this publication without disclosure by any electronic means it deems necessary and may change those means without notice at any time. If you have received this publication and are not the intended subscriber, please contact


The Mauldin Economics website, Yield Shark, Thoughts from the Frontline, Patrick Cox’s Tech Digest, Outside the Box, Over My Shoulder, World Money Analyst, Street Freak, ETF 20/20, Just One Trade, Transformational Technology Alert, Rational Bear, The 10th Man, Connecting the Dots, This Week in Geopolitics, Stray Reflections, and Conversations are published by Mauldin Economics, LLC. Information contained in such publications is obtained from sources believed to be reliable, but its accuracy cannot be guaranteed. The information contained in such publications is not intended to constitute individual investment advice and is not designed to meet your personal financial situation. The opinions expressed in such publications are those of the publisher and are subject to change without notice. The information in such publications may become outdated and there is no obligation to update any such information. You are advised to discuss with your financial advisers your investment options and whether any investment is suitable for your specific needs prior to making any investments.
John Mauldin, Mauldin Economics, LLC and other entities in which he has an interest, employees, officers, family, and associates may from time to time have positions in the securities or commodities covered in these publications or web site. Corporate policies are in effect that attempt to avoid potential conflicts of interest and resolve conflicts of interest that do arise in a timely fashion.
Mauldin Economics, LLC reserves the right to cancel any subscription at any time, and if it does so it will promptly refund to the subscriber the amount of the subscription payment previously received relating to the remaining subscription period. Cancellation of a subscription may result from any unauthorized use or reproduction or rebroadcast of any Mauldin Economics publication or website, any infringement or misappropriation of Mauldin Economics, LLC’s proprietary rights, or any other reason determined in the sole discretion of Mauldin Economics, LLC.

Affiliate Notice

Mauldin Economics has affiliate agreements in place that may include fee sharing. If you have a website or newsletter and would like to be considered for inclusion in the Mauldin Economics affiliate program, please go to Likewise, from time to time Mauldin Economics may engage in affiliate programs offered by other companies, though corporate policy firmly dictates that such agreements will have no influence on any product or service recommendations, nor alter the pricing that would otherwise be available in absence of such an agreement. As always, it is important that you do your own due diligence before transacting any business with any firm, for any product or service.

© Copyright 2018 Mauldin Economics